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A signiﬁcant fraction of disease-causing mutations affects pre-mRNA splicing.
These mutations can generate both aberrant and correct transcripts, the level of
which varies among different patients. An inverse correlation was found between
this level and disease severity. The mechanism underlying this variability was
suggested to involve splicing factors known to promote exon skipping and /or
exon inclusion, indicating a role for splicing regulation as a genetic modiﬁer.
We previously demonstrated that overexpression of Htra2-beta1 and SC35 splicing
factors increase the level of normal CFTR transcripts, in CF-derived epithelial
cells carrying the 3849+10kb C->T splicing mutation. This led to activation of the
CFTR channel and restoration of its function. An increase in the level of normal
CFTR transcripts as well as CFTR functional restoration was also obtained by
sodium butyrate, a histone deacetylase (HDAC) inhibitor, known to up-regulate the
expression of splicing factors. We subsequently searched for small molecules with
therapeutic potential. Hence we analyzed the effect of kinetin, a plant cytokinin,
EGCG, a green tea antioxidant and tocotrienol (vitamin E) as well as valproic
acid, another HDAC inhibitor used in epilepsy and cancer therapy. Our results
show a signiﬁcant CFTR functional restoration as determined by chloride efﬂux
measurements following treatment with kinetin, EGCG and tocotrienol. The effect
of these molecules on CFTR RNA level and on the splicing pattern of mRNA
transcribed from the 3849+10kb C->T allele in the CF-derived epithelial cells will
be presented. In conclusion, our results highlight the therapeutic potential of splicing
modulation for CF and other genetic diseases caused by splicing mutations.
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Exciting developments in gene therapy for CF have been tempered by accusations
that proponents are creating unrealistic expectations. Yet to date there has been
no empirical attempt to explore knowledge and views among adults with CF. This
study reports on such issues in a single centre, being part of a larger multicentre
survey (due to complete – Jan 2008).
Adults with CF (N= 72; 16−48 yrs) completed questionnaires during clinic (67%
response rate). There was good matching between the sample and clinic populations.
General knowledge was high, although most adults (71%) wanted to know more;
speciﬁcally if gene therapy would beneﬁt them and how it would work (76%).
46% thought it ‘unlikely’ that they would treated. Those thought most likely to
beneﬁt were children <5 years and the unborn (77%). At present almost two-
thirds received most of their information from the UK CF Trust. However, the
overwhelming majority wanted to learn and discuss issues in more detail with their
team; 44% wanting this to be part of standard care. Respondents who were older
and who believed that it would take longer for gene therapy to be available, were
less likely to think that they would one day receive gene therapy. Whether someone
believes they will be treated by gene therapy was associated with how optimistic
they felt. Optimism was also signiﬁcantly positively associated with seeking out
information (r = 0.375; p< 0.01). In contrast to previous work with parents, adults
with CF seemed not to view gene therapy as a potential cure. Qualitative data
suggested that participants wanted to know more about gene therapy, believing
their knowledge to be inaccurate.
Implications for clinical practice, psychological well-being and treatment adherence
will be discussed.
